1
|
Mesch S, Walter D, Laux-Biehlmann A, Basting D, Flanagan S, Miyatake Ondozabal H, Bäurle S, Pearson C, Jenkins J, Elves P, Hess S, Coelho AM, Rotgeri A, Bothe U, Nawaz S, Zollner TM, Steinmeyer A. Discovery of BAY-390, a Selective CNS Penetrant Chemical Probe as Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonist. J Med Chem 2023; 66:1583-1600. [PMID: 36622903 PMCID: PMC9884088 DOI: 10.1021/acs.jmedchem.2c01830] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Indexed: 01/10/2023]
Abstract
Transient receptor potential ankyrin 1 (TRPA1) is a voltage-dependent, ligand-gated ion channel, and activation thereof is linked to a variety of painful conditions. Preclinical studies have demonstrated the role of TRPA1 receptors in a broad range of animal models of acute, inflammatory, and neuropathic pain. In addition, a clinical study using the TRPA1 antagonist GRC-17536 (Glenmark Pharmaceuticals) demonstrated efficacy in a subgroup of patients with painful diabetic neuropathy. Consequently, there is an increasing interest in TRPA1 inhibitors as potential analgesics. Herein, we report the identification of a fragment-like hit from a high-throughput screening (HTS) campaign and subsequent optimization to provide a novel and brain-penetrant TRPA1 inhibitor (compound 18, BAY-390), which is now being made available to the research community as an open-source in vivo probe.
Collapse
Affiliation(s)
- Stefanie Mesch
- Pharmaceutical
R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Daryl Walter
- Discovery
Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
| | - Alexis Laux-Biehlmann
- Exploratory
Pathobiology, RED preMED, R&D, Bayer
AG, Aprather Weg 18a, 42113 Wuppertal, Germany
| | - Daniel Basting
- Pharmaceutical
R&D, Drug Discovery, Lead Identification and Characterization, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany
| | - Stuart Flanagan
- Discovery
Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
| | - Hideki Miyatake Ondozabal
- Pharmaceutical
R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Stefan Bäurle
- Pharmaceutical
R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Christopher Pearson
- Discovery
Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
| | - James Jenkins
- Discovery
Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
| | - Philip Elves
- Discovery
Chemistry, Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K.
| | - Stephen Hess
- In
Vitro Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen
7, 22419 Hamburg, Germany
| | - Anne-Marie Coelho
- In Vivo Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Andrea Rotgeri
- Pharmaceutical
R&D, Early Development, Drug Metabolism and Pharmacokinetics, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Ulrich Bothe
- Pharmaceutical
R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Schanila Nawaz
- In Vivo Pharmacology, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Thomas M. Zollner
- Pharmaceutical
R&D, Preclinical Research, Therapeutic Area Endocrinology, Metabolism
and Reproductive Health, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| | - Andreas Steinmeyer
- Pharmaceutical
R&D, Drug Discovery, Medicinal Chemistry, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
| |
Collapse
|
2
|
Giorgi S, Nikolaeva-Koleva M, Alarcón-Alarcón D, Butrón L, González-Rodríguez S. Is TRPA1 Burning Down TRPV1 as Druggable Target for the Treatment of Chronic Pain? Int J Mol Sci 2019; 20:ijms20122906. [PMID: 31197115 PMCID: PMC6627658 DOI: 10.3390/ijms20122906] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/12/2019] [Accepted: 06/13/2019] [Indexed: 12/14/2022] Open
Abstract
Over the last decades, a great array of molecular mediators have been identified as potential targets for the treatment of chronic pain. Among these mediators, transient receptor potential (TRP) channel superfamily members have been thoroughly studied. Namely, the nonselective cationic channel, transient receptor potential ankyrin subtype 1 (TRPA1), has been described as a chemical nocisensor involved in noxious cold and mechanical sensation and as rivalling TRPV1, which traditionally has been considered as the most important TRP channel involved in nociceptive transduction. However, few TRPA1-related drugs have succeeded in clinical trials. In the present review, we attempt to discuss the latest data on the topic and future directions for pharmacological intervention.
Collapse
Affiliation(s)
- Simona Giorgi
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Avda de la Univesidad s/n, Universidad Miguel Hernández, 03202 Elche, Spain.
| | - Magdalena Nikolaeva-Koleva
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Avda de la Univesidad s/n, Universidad Miguel Hernández, 03202 Elche, Spain.
- AntalGenics, SL. Ed. Quorum III, Parque Científico Universidad Miguel Hernández, Avda de la Universidad s/n, 03202 Elche, Spain.
| | - David Alarcón-Alarcón
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Avda de la Univesidad s/n, Universidad Miguel Hernández, 03202 Elche, Spain.
| | - Laura Butrón
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Avda de la Univesidad s/n, Universidad Miguel Hernández, 03202 Elche, Spain.
| | - Sara González-Rodríguez
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Avda de la Univesidad s/n, Universidad Miguel Hernández, 03202 Elche, Spain.
| |
Collapse
|
3
|
TRPA1 ankyrin repeat six interacts with a small molecule inhibitor chemotype. Proc Natl Acad Sci U S A 2018; 115:12301-12306. [PMID: 30429323 DOI: 10.1073/pnas.1808142115] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
TRPA1, a member of the transient receptor potential channel (TRP) family, is genetically linked to pain in humans, and small molecule inhibitors are efficacious in preclinical animal models of inflammatory pain. These findings have driven significant interest in development of selective TRPA1 inhibitors as potential analgesics. The majority of TRPA1 inhibitors characterized to date have been reported to interact with the S5 transmembrane helices forming part of the pore region of the channel. However, the development of many of these inhibitors as clinical drug candidates has been prevented by high lipophilicity, low solubility, and poor pharmacokinetic profiles. Identification of alternate compound interacting sites on TRPA1 provides the opportunity to develop structurally distinct modulators with novel structure-activity relationships and more desirable physiochemical properties. In this paper, we have identified a previously undescribed potent and selective small molecule thiadiazole structural class of TRPA1 inhibitor. Using species ortholog chimeric and mutagenesis strategies, we narrowed down the site of interaction to ankyrinR #6 within the distal N-terminal region of TRPA1. To identify the individual amino acid residues involved, we generated a computational model of the ankyrinR domain. This model was used predictively to identify three critical amino acids in human TRPA1, G238, N249, and K270, which were confirmed by mutagenesis to account for compound activity. These findings establish a small molecule interaction region on TRPA1, expanding potential avenues for developing TRPA1 inhibitor analgesics and for probing the mechanism of channel gating.
Collapse
|
4
|
Chłoń-Rzepa G, Ślusarczyk M, Jankowska A, Gawalska A, Bucki A, Kołaczkowski M, Świerczek A, Pociecha K, Wyska E, Zygmunt M, Kazek G, Sałat K, Pawłowski M. Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. Eur J Med Chem 2018; 158:517-533. [PMID: 30245393 DOI: 10.1016/j.ejmech.2018.09.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 09/06/2018] [Accepted: 09/08/2018] [Indexed: 12/31/2022]
Abstract
A series of novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids designed using a structure-based computational approach was synthesized and assayed to evaluate their ability to block human TRPA1 channel and inhibit PDE4B/7A activity. We identified compounds 16 and 27 which showed higher potency against TRPA1 compared to HC-030031. In turn, compound 36 was the most promising multifunctional TRPA1 antagonist and PDE4B/7A dual inhibitor with IC50 values in the range of that of the reference rolipram and BRL-50481, respectively. Compound 36 as a combined TRPA1/PDE4B/PDE7A ligand was characterized by a distinct binding mode in comparison to 16 and 27, in the given protein targets. The inhibition of both cAMP-specific PDE isoenzymes resulted in a strong anti-TNF-α effect of 36in vivo. Moreover, the potent anti-inflammatory and analgesic efficacy of 36 was observed in animal models of pain and inflammation (formalin test in mice and carrageenan-induced paw edema in rats). This compound also displayed significant antiallodynic properties in the early phase of chemotherapy-induced peripheral neuropathy in mice. In turn, the pure TRPA1 antagonists 16 and 27 revealed a statistically significant antiallodynic effect in the formalin test and in the von Frey test performed in both phases of oxaliplatin-induced allodynia. Antiallodynic activity of the test compounds 16, 27 and 36 was observed at a dose range comparable to that of the reference drug - pregabalin. In conclusion, the proposed approach of pain treatment based on the concomitant blocking of TRPA1 channel and PDE4B/7A inhibitory activity appears to be interesting research direction for the future search for novel analgesics.
Collapse
Affiliation(s)
- Grażyna Chłoń-Rzepa
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland.
| | - Marietta Ślusarczyk
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Agnieszka Jankowska
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Alicja Gawalska
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Adam Bucki
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Marcin Kołaczkowski
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Artur Świerczek
- Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Krzysztof Pociecha
- Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Elżbieta Wyska
- Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Małgorzata Zygmunt
- Department of Pharmacological Screening, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Grzegorz Kazek
- Department of Pharmacological Screening, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Kinga Sałat
- Department of Pharmacodynamics, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| | - Maciej Pawłowski
- Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna str, 30-688, Kraków, Poland
| |
Collapse
|
5
|
Moore C, Gupta R, Jordt SE, Chen Y, Liedtke WB. Regulation of Pain and Itch by TRP Channels. Neurosci Bull 2018; 34:120-142. [PMID: 29282613 PMCID: PMC5799130 DOI: 10.1007/s12264-017-0200-8] [Citation(s) in RCA: 191] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 10/27/2017] [Indexed: 02/07/2023] Open
Abstract
Nociception is an important physiological process that detects harmful signals and results in pain perception. In this review, we discuss important experimental evidence involving some TRP ion channels as molecular sensors of chemical, thermal, and mechanical noxious stimuli to evoke the pain and itch sensations. Among them are the TRPA1 channel, members of the vanilloid subfamily (TRPV1, TRPV3, and TRPV4), and finally members of the melastatin group (TRPM2, TRPM3, and TRPM8). Given that pain and itch are pro-survival, evolutionarily-honed protective mechanisms, care has to be exercised when developing inhibitory/modulatory compounds targeting specific pain/itch-TRPs so that physiological protective mechanisms are not disabled to a degree that stimulus-mediated injury can occur. Such events have impeded the development of safe and effective TRPV1-modulating compounds and have diverted substantial resources. A beneficial outcome can be readily accomplished via simple dosing strategies, and also by incorporating medicinal chemistry design features during compound design and synthesis. Beyond clinical use, where compounds that target more than one channel might have a place and possibly have advantageous features, highly specific and high-potency compounds will be helpful in mechanistic discovery at the structure-function level.
Collapse
Affiliation(s)
- Carlene Moore
- Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA
| | - Rupali Gupta
- Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA
| | - Sven-Eric Jordt
- Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA
| | - Yong Chen
- Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA.
| | - Wolfgang B Liedtke
- Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA.
- Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA.
| |
Collapse
|
6
|
Pryde DC, Marron BE, West CW, Reister S, Amato G, Yoger K, Antonio B, Padilla K, Cox PJ, Turner J, Warmus JS, Swain NA, Omoto K, Mahoney JH, Gerlach AC. Discovery of a Series of Indazole TRPA1 Antagonists. ACS Med Chem Lett 2017. [PMID: 28626530 DOI: 10.1021/acsmedchemlett.7b00140] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
A series of TRPA1 antagonists is described which has as its core structure an indazole moiety. The physical properties and in vitro DMPK profiles are discussed. Good in vivo exposure was obtained with several analogs, allowing efficacy to be assessed in rodent models of inflammatory pain. Two compounds showed significant activity in these models when administered either systemically or topically. Protein chimeras were constructed to indicate compounds from the series bound in the S5 region of the channel, and a computational docking model was used to propose a binding mode for example compounds.
Collapse
Affiliation(s)
- David C. Pryde
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, U.K
| | - Brian E. Marron
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Christopher W. West
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Steven Reister
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - George Amato
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Katrina Yoger
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Brett Antonio
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Karen Padilla
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Peter J. Cox
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, U.K
| | - Jamie Turner
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, U.K
| | - Joseph S. Warmus
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Groton, Connecticut 06340, United States
| | - Nigel A. Swain
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, U.K
| | - Kiyoyuki Omoto
- Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, U.K
| | - John H. Mahoney
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| | - Aaron C. Gerlach
- Pfizer Neuroscience and Pain Research Unit, 4222 Emperor Boulevard, Suite 350, Durham, North Carolina NC27703, United States
| |
Collapse
|
7
|
Identification of a putative binding site critical for general anesthetic activation of TRPA1. Proc Natl Acad Sci U S A 2017; 114:3762-3767. [PMID: 28320952 DOI: 10.1073/pnas.1618144114] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
General anesthetics suppress CNS activity by modulating the function of membrane ion channels, in particular, by enhancing activity of GABAA receptors. In contrast, several volatile (isoflurane, desflurane) and i.v. (propofol) general anesthetics excite peripheral sensory nerves to cause pain and irritation upon administration. These noxious anesthetics activate transient receptor potential ankyrin repeat 1 (TRPA1), a major nociceptive ion channel, but the underlying mechanisms and site of action are unknown. Here we exploit the observation that pungent anesthetics activate mammalian but not Drosophila TRPA1. Analysis of chimeric Drosophila and mouse TRPA1 channels reveal a critical role for the fifth transmembrane domain (S5) in sensing anesthetics. Interestingly, we show that anesthetics share with the antagonist A-967079 a potential binding pocket lined by residues in the S5, S6, and the first pore helix; isoflurane competitively disrupts A-967079 antagonism, and introducing these mammalian TRPA1 residues into dTRPA1 recapitulates anesthetic agonism. Furthermore, molecular modeling predicts that isoflurane and propofol bind to this pocket by forming H-bond and halogen-bond interactions with Ser-876, Met-915, and Met-956. Mutagenizing Met-915 or Met-956 selectively abolishes activation by isoflurane and propofol without affecting actions of A-967079 or the agonist, menthol. Thus, our combined experimental and computational results reveal the potential binding mode of noxious general anesthetics at TRPA1. These data may provide a structural basis for designing drugs to counter the noxious and vasorelaxant properties of general anesthetics and may prove useful in understanding effects of anesthetics on related ion channels.
Collapse
|
8
|
Diaz-Franulic I, Poblete H, Miño-Galaz G, González C, Latorre R. Allosterism and Structure in Thermally Activated Transient Receptor Potential Channels. Annu Rev Biophys 2016; 45:371-98. [DOI: 10.1146/annurev-biophys-062215-011034] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Ignacio Diaz-Franulic
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias Biológicas, Universidad Andres Bello, Santiago 8370146, Chile
- Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2366103, Chile; ,
- Fraunhofer Chile Research, Las Condes 7550296, Santiago, Chile
| | - Horacio Poblete
- Institute of Computational Comparative Medicine, Nanotechnology Innovation Center of Kansas State, Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506-5802
| | - Germán Miño-Galaz
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias Biológicas, Universidad Andres Bello, Santiago 8370146, Chile
- Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2366103, Chile; ,
| | - Carlos González
- Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2366103, Chile; ,
| | - Ramón Latorre
- Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2366103, Chile; ,
| |
Collapse
|
9
|
Pryde DC, Marron B, West CG, Reister S, Amato G, Yoger K, Padilla K, Turner J, Swain NA, Cox PJ, Skerratt SE, Ryckmans T, Blakemore DC, Warmus J, Gerlach AC. The discovery of a potent series of carboxamide TRPA1 antagonists. MEDCHEMCOMM 2016. [DOI: 10.1039/c6md00387g] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Potent and selective carboxamide TRPA1 antagonists were identified by high throughput screening, with efficacy demonstrated in a topical inflammation model.
Collapse
Affiliation(s)
- D. C. Pryde
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | | | | | | | | | | | | | - J. Turner
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - N. A. Swain
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - P. J. Cox
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - S. E. Skerratt
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - T. Ryckmans
- Pfizer Worldwide Medicinal Chemistry
- Sandwich
- UK
| | - D. C. Blakemore
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - J. Warmus
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Groton
- USA
| | | |
Collapse
|
10
|
Laursen WJ, Anderson EO, Hoffstaetter LJ, Bagriantsev SN, Gracheva EO. Species-specific temperature sensitivity of TRPA1. Temperature (Austin) 2015; 2:214-26. [PMID: 27227025 PMCID: PMC4843866 DOI: 10.1080/23328940.2014.1000702] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Revised: 12/16/2014] [Accepted: 12/16/2014] [Indexed: 11/25/2022] Open
Abstract
Transient receptor potential ankyrin 1 (TRPA1) is a polymodal ion channel sensitive to temperature and chemical stimuli. The importance of temperature and aversive chemical detection for survival has driven the evolutionary diversity of TRPA1 sensitivity. This diversity can be observed in the various roles of TRPA1 in different species, where it is proposed to act as a temperature-insensitive chemosensor, a heat transducer, a noxious cold transducer, or a detector of low-intensity heat for prey localization. Exploring the variation of TRPA1 functions among species provides evolutionary insight into molecular mechanisms that fine-tune thermal and chemical sensitivity, and offers an opportunity to address basic principles of temperature gating in ion channels. A decade of research has yielded a number of hypotheses describing physiological roles of TRPA1, modulators of its activity, and biophysical principles of gating. This review surveys the diversity of TRPA1 adaptations across evolutionary taxa and explores possible mechanisms of TRPA1 activation.
Collapse
Affiliation(s)
- Willem J Laursen
- Department of Cellular and Molecular Physiology; Yale University School of Medicine; New Haven, CT, USA; Program in Cellular Neuroscience; Neurodegeneration and Repair; Yale University School of Medicine; New Haven, CT, USA
| | - Evan O Anderson
- Department of Cellular and Molecular Physiology; Yale University School of Medicine ; New Haven, CT, USA
| | - Lydia J Hoffstaetter
- Department of Cellular and Molecular Physiology; Yale University School of Medicine; New Haven, CT, USA; Program in Cellular Neuroscience; Neurodegeneration and Repair; Yale University School of Medicine; New Haven, CT, USA
| | - Sviatoslav N Bagriantsev
- Department of Cellular and Molecular Physiology; Yale University School of Medicine ; New Haven, CT, USA
| | - Elena O Gracheva
- Department of Cellular and Molecular Physiology; Yale University School of Medicine; New Haven, CT, USA; Program in Cellular Neuroscience; Neurodegeneration and Repair; Yale University School of Medicine; New Haven, CT, USA
| |
Collapse
|